Marshall Edwards Issued New Method of Use Patent for Lead Oncology Drug Candidate ME-344 - PR Newswire - sacbee.com

Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the U.S. Patent and Trademark Office has issued a new method of use patent, U.S. Patent No. 8,084,628, covering a number of the Company's mitochondrial inhibitor compounds, including lead drug candidate ME-344, for the treatment of cancer or a tumor mass. The patent is expected to provide protection until September 2025.